Kovac Viljem, Dodic-Fikfak Metoda, Arneric Niko, Dolzan Vita, Franko Alenka
Institute of Oncology Ljubljana, Zaloška cesta 2, Ljubljana, Slovenia.
Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia.
Radiol Oncol. 2015 Aug 21;49(3):279-85. doi: 10.1515/raon-2015-0019. eCollection 2015 Sep.
Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the potential applicability of fibulin-3 plasma levels as a biomarker of response to treatment and its prognostic value for progressive disease within 18 months. The potential applicability of fibulin-3 in comparison with or in addition to soluble mesothelin-related peptides (SMRP) was also assessed.
The study included 78 MM patients treated at the Institute of Oncology Ljubljana between 2007 and 2011. Fibulin-3 levels in plasma samples obtained before treatment and in various responses to treatment were measured with the enzyme-linked immunosorbent assay.
In patients evaluated before the treatment, fibulin-3 levels were not influenced by histopathological sub-types, tumour stages or the presence of metastatic disease. Significantly higher fibulin-3 levels were found in progressive disease as compared to the levels before treatment (Mann-Whitney [U] test = 472.50, p = 0.003), in complete response to treatment (U = 42.00, p = 0.010), and in stable disease (U = 542.00, p = 0.001). Patients with fibulin-3 levels exceeding 34.25 ng/ml before treatment had more than four times higher probability for developing progressive disease within 18 months (odds ratio [OR] = 4.35, 95% confidence interval [CI] 1.56-12.13). Additionally, patients with fibulin-3 levels above 34.25 ng/ml after treatment with complete response or stable disease had increased odds for progressive disease within 18 months (OR = 6.94, 95% CI 0.99-48.55 and OR = 4.39, 95% CI 1.63-11.81, respectively).
Our findings suggest that in addition to SMRP fibulin-3 could also be helpful in detecting the progression of MM.
纤维连接蛋白-3是恶性间皮瘤（MM）一种新的潜在生物标志物。本研究评估了纤维连接蛋白-3血浆水平作为治疗反应生物标志物的潜在适用性及其对18个月内疾病进展的预后价值。还评估了纤维连接蛋白-3与可溶性间皮素相关肽（SMRP）相比或联合使用时的潜在适用性。
本研究纳入了2007年至2011年在卢布尔雅那肿瘤研究所接受治疗的78例MM患者。采用酶联免疫吸附测定法测量治疗前及各种治疗反应时采集的血浆样本中纤维连接蛋白-3的水平。
在治疗前评估的患者中，纤维连接蛋白-3水平不受组织病理学亚型、肿瘤分期或转移性疾病存在情况的影响。与治疗前水平相比，疾病进展时纤维连接蛋白-3水平显著升高（曼-惠特尼[U]检验=472.50，p=0.003），治疗完全缓解时（U=42.00，p=0.010）以及疾病稳定时（U=542.00，p=0.001）也是如此。治疗前纤维连接蛋白-3水平超过34.25 ng/ml的患者在18个月内发生疾病进展的可能性高出四倍多（比值比[OR]=4.35，95%置信区间[CI]1.56-12.13）。此外，治疗后完全缓解或疾病稳定且纤维连接蛋白-3水平高于34.25 ng/ml的患者在18个月内发生疾病进展的几率增加（OR分别为6.94，95%CI 0.99-48.55和OR=4.39，95%CI 1.63-11.81）。
我们的研究结果表明，除SMRP外，纤维连接蛋白-3在检测MM进展方面可能也有帮助。
